Japan’s First! A Complete Guide to “Alli” – The First Medication to Reduce Visceral Fat: Effects, Side Effects, and Evidence
On April 8, 2024, “Alli,” Japan’s first drug aimed at reducing visceral fat, was released. Visceral fat is known to increase the risk of lifestyle-related diseases and has been a challenging issue for those who could not reduce it through exercise or dietary measures alone. “Alli” has been eagerly awaited as a solution. However, many questions arise: Is “Alli” truly effective? What are the side effects? Who can take it? Let’s dive deep into the details of “Alli.” What is Alli? Overview of Alli Alli, developed and sold by Taisho Pharmaceutical, is a medication designed to reduce visceral fat. Its active ingredient, Orlistat, blocks the absorption of fats, thus reducing visceral fat, waist circumference, and body weight. Orlistat is approved in over 100 countries globally and is established for its safety and efficacy. Although previously available only as a prescription drug in Japan, it has now been released as an over-the-counter medication for the first time. Effects of Alli Alli can block about 25-30% of fat absorption from your diet. The expected benefits include: In clinical trials, those taking Alli lost on average more than twice as much weight compared to those who took a placebo. Specifically, the placebo group […]